LIVEN · Liven Pharma Limited
financial results for the Year Ended June 30, 2026
- Filed
- 5 October 2026 at 8:04 am
- Category
- Financials
- Sentiment
- Good
- Impact
- High
AI executive summary
Liven Pharma Limited reported its annual financial results for the year ended June 30, 2026, showing a net loss after tax of PKR 31.14 million compared to a loss of PKR 584.46 million in the previous year. Sales decreased to PKR 105.81 million from PKR 127.27 million YoY, while the loss per share improved to PKR 0.28 from PKR 7.11.
Key takeaways
- Sales for the year ended June 30, 2026, decreased 16.9% YoY to PKR 105.81 million compared to PKR 127.27 million in FY2025.
- Net loss after tax narrowed significantly to PKR 31.14 million in FY2026 compared to a net loss of PKR 584.46 million in FY2025.
- Loss before taxation stood at PKR 66.32 million for FY2026 compared to PKR 492.19 million in the prior year.
- Basic and diluted loss per share improved to PKR 0.28 for FY2026 from PKR 7.11 (restated) in FY2025.
Filing details
Financial results
Annual · Audited · Standalone · 30 June 2026
Figures in Rupees
Reporting period
Year
- Income
- 105,806,555 (prior 127,271,949)
- Profit after tax
- -31,138,687 (prior -584,459,523)
- EPS
- -0.28 (prior -7.11)
Dividend and entitlement
- Type
- None
- Entitlement date
- 18 October 2026
- Book closure
- 19 October 2026 – 26 October 2026
- Notes
- The document declares Nil for cash dividend, bonus shares, and right shares.
- #financial-results
- #annual-report
- #liven-pharma
- #earnings
This summary is AI-generated and may contain errors or omissions. Review the official PSX filing before making an investment decision.